Chester County News and Community Website
RADNOR, PA — Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) has released its financial results for the third quarter ended September 30, 2024, detailing significant progress and strategic shifts in its operations. …
Marinus Pharmaceuticals Reports Q3 2024 Financial Results and Strategic Developments Read More RADNOR, PA — Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) has announced that its Phase 3 TrustTSC trial, which evaluated the use of oral ganaxolone for treating seizures in individuals with tuberous …
Marinus Pharmaceuticals Faces Setback with Phase 3 TrustTSC Trial Read More RADNOR, PA — Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) showcased new findings from its pivotal Phase 3 RAISE trial at the Neurocritical Care Society Annual Meeting, highlighting the potential of intravenous …
Marinus Pharmaceuticals Unveils Promising Phase 3 Trial Results for IV Ganaxolone in Treating Refractory Status Epilepticus Read More RADNOR, PA — Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) has fortified its intellectual property holdings with the United States Patent and Trademark Office’s issuance of a new patent for ZTALMY® (ganaxolone) oral …
Marinus Pharmaceuticals Expands Intellectual Property Portfolio with New ZTALMY® Patent Read More RADNOR, PA — Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) is set to present significant findings from its Phase 3 RAISE trial on the treatment of refractory status epilepticus at the Neurocritical Care …
Marinus Pharmaceuticals to Present New Epilepsy Treatment Data at Upcoming Conference Read More RADNOR, PA — Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) has announced the issuance of inducement stock options to a new employee, as part of the company’s strategic compensation approach. The company’s Board …
Marinus Pharmaceuticals Issues Stock Options to New Employee Read More RADNOR, PA — Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) is set to host its Investor & Analyst Day on September 20 in New York, where the company’s leadership and key opinion leaders …
Marinus Pharmaceuticals to Outline Strategic Vision at Investor & Analyst Day Read More RADNOR, PA — Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) has announced its participation in a fireside chat at the 2024 Cantor Global Healthcare Conference.
Marinus Pharmaceuticals to Present at 2024 Cantor Global Healthcare Conference Read More RADNOR, PA — Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) is set to hold an Investor and Analyst Day on Friday, September 20, from 9:00 a.m. to 12:00 p.m. Eastern Time. This …
Marinus Pharmaceuticals Hosts Investor and Analyst Day Read More RADNOR, PA — Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) recenlty reported its financial results for the second quarter ending June 30, 2024, alongside significant business highlights that underscore the company’s progress in …
Marinus Pharmaceuticals Reports Robust Q2 2024 Financial Results and Business Progress Read More